Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease

@article{Hauser2009SafetyAT,
  title={Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease},
  author={Robert A. Hauser and Juliana Bronzova and Cristina Sampaio and Anthony E. Lang and Olivier Rascol and And Ad Theeuwes and Serge V van de Witte},
  journal={European Neurology},
  year={2009},
  volume={62},
  pages={40 - 48}
}
Aims: To investigate the safety and tolerability of pardoprunox (SLV308), a novel partial dopamine agonist, as an adjunct to levodopa in patients with advanced Parkinson’s disease, using two titration schedules. Methods: Patients were randomized to pardoprunox (n = 51) or placebo (n = 11). Pardoprunox was titrated to the highest tolerated dose (range, 0.3–42 mg/day) over 7 weeks, using a gradual dose escalation without intermediate steps (group 1) or with intermediate steps (group 2). Results… 

Figures and Tables from this paper

Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
TLDR
Pardoprunox significantly improved motor symptoms in patients with early Parkinson's disease, but further investigation into the dose and titration schedule is required to improve tolerability.
Therapies for dopaminergic‐induced dyskinesias in parkinson disease
TLDR
These findings support the hypothesis of glutamate overactivity in the development of dyskinesias and suggest more continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions.
Dopamine receptor agonists for Parkinson's disease
TLDR
This review summarizes pre-clinical and clinical data on second-generation, first-line non-ergolinic DA agonists and their motor, non-motor and putative neuroprotective effects and addressed the anti-parkinsonian potential of recently developedDA agonists that reached Phase II and III clinical trials.
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
TLDR
Novel therapies for LIDs in Parkinson’s disease are focused on, based mainly on agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in testing or clinical development.
Nitric oxide, a new player in L-DOPA-induced dyskinesia?
TLDR
This review attempts to highlight the role of nitric oxide (NO) in PD and provide a comprehensive picture of recent preclinical findings from the authors' group and others showing its potential involvement in dyskinesia.
Emerging therapies for Parkinson's disease.
TLDR
A variety of medical and nonmedical interventions in different phases of clinical development provide an interesting and promising portfolio of emerging therapies for Parkinson's disease.
Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis
TLDR
The present study showed that CDS was beneficial in the treatment of PD patients with motor complications, but the incidence of the side events is more common than placebo.
...
1
2
3
...

References

SHOWING 1-10 OF 20 REFERENCES
Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial
TLDR
This study provides additional level I evidence of the usefulness of pramipexole, suggests a particular tremorlytic and a possible antidepressant action of this compound, and addresses for the first time its efficacy and safety during long‐term administration in advanced PD.
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
TLDR
Ropinirole permits a reduction in L-dopa dose with enhanced clinical benefit for PD patients with motor fluctuations and delays the possibility of adverse effect onset.
Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
TLDR
Pramipexole improved motor function of patients during "on" and"off" periods, decreased the time spent in "off") periods, reduced the severity of "off"periods, decreased disability and PD severity as assessed by the Unified Parkinson Disease Rating Scale, and permitted a reduction in levodopa dosage.
Advanced Parkinson disease treated with rotigotine transdermal system
TLDR
Transdermal rotigotine significantly improved “off” time in subjects with Parkinson disease not optimally controlled with levodopa and was safe and well tolerated, with typical dopaminergic side effects and occasional application site reactions.
Bromocriptine: Low‐dose therapy in Parkinson disease
TLDR
Low-dose bromocriptine therapy is effective, does not induce significant dyskinesia nor on-off phenomenon, and is probably an alternative to levodopa as a drug of first choice in Parkinson disease.
Limitations of current Parkinson's disease therapy
TLDR
The current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety.
A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia
TLDR
It is argued that patients might not be improved if off time is reduced only to the extent that unwanted dyskinesia is increased, so a home diary should include an assessment of dyskine to provide an accurate reflection of clinical status over a period of time.
The spectrum of levodopa-induced dyskinesias.
  • S. Fahn
  • Psychology, Medicine
    Annals of neurology
  • 2000
The most common types of levodopa-induced dyskinesias in patients with Parkinson's disease (PD) are chorea and dystonia, and often the two types are intermixed. Myoclonus is a far less common
...
1
2
...